SEMA3C and neoplasm: As shown in Fig 5C, we have found that SEMA3C ASO treatment resulted in reduced levels of the endothelial marker CD31 in LNCaP xenografts post‐castration, suggesting that reduced tumor growth may in part be mediated by anti‐angiogenic effects of SEMA3C inhibition.